GLP-1RA for heart nerve damage in type 2 diabetes
Part of Hormones & metabolism clinical trials.
This trial tests whether a type of diabetes medicine called GLP-1RA can help prevent or improve nerve damage in the heart caused by diabetes. It is for people with type 2 diabetes who are overweight or obese.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have type 2 diabetes.
- You are overweight or obese.
- You are not pregnant or breastfeeding.
- You do not have certain heart rhythm problems or take medicines for them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a GLP-1 medication (a type of diabetes drug) can help protect nerves in the heart from damage caused by diabetes. If you have type 2 diabetes and are overweight, this trial might help researchers understand if this medication improves how your heart's nervous system works.
This trial tests how a new type of diabetes medicine, called a GLP-1 receptor agonist, affects heart artery health in people with type 2 diabetes who recently had a heart procedure. It aims to find out if adding this medicine can further protect the heart and improve recovery.
This trial tests whether a GLP-1 agonist (a type of diabetes medicine that also helps with weight loss) is safe and effective for people with spinal cord injury and type 2 diabetes who are not on other glucose-lowering drugs.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study tests whether a GLP-1 receptor agonist (a medication used for diabetes and weight loss) can reduce heart damage during or after planned non-cardiac surgery. It may help patients with heart risk undergoing intermediate to high-risk procedures.
This study tests if a weekly injection (semaglutide) combined with an exercise program can help reduce fat stored in the heart and muscles in people with type 2 diabetes. It may improve how well your body handles sugar and lowers your risk for heart problems.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.